ATIMPRIMOD:
|
Protocol No. |
Title |
Sites Opened |
Total # of Sites |
| CP-101 | An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients with Refractory or Relapsed Multiple Myeloma | 4 |
4 |
| CP-106 | A Phase II Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients with Low to Intermediate Grade Neuroendocrine Carcinoma |
3 |
8 |
L-ANNAMYCIN:
|
Protocol No. |
Title |
Sites Opened |
Total # of Sites |
| CP-103 | Phase I/II Study of Liposomal Annamycin in Patients withRefractory or Relapsed Acute Lymphocytic Leukemia | 3 | 3 |
| CP-105 | Phase I Study of Liposomal Annamycin in Children and Young Adults with Refractory or Relapsed Acute Lymphocytic Leukemia or Acute Myelogenous Leukemia |
2 |
10 |